| Literature DB >> 29510988 |
Presha Rajbhandari1,2, Gonzalo Lopez1,3, Claudia Capdevila1, Beatrice Salvatori1, Jiyang Yu1,4, Ruth Rodriguez-Barrueco5,6, Daniel Martinez3, Mark Yarmarkovich3, Nina Weichert-Leahey7, Brian J Abraham8, Mariano J Alvarez1, Archana Iyer1, Jo Lynne Harenza3, Derek Oldridge3, Katleen De Preter9, Jan Koster10, Shahab Asgharzadeh11,12, Robert C Seeger11,12, Jun S Wei13, Javed Khan13, Jo Vandesompele9, Pieter Mestdagh9, Rogier Versteeg10, A Thomas Look7, Richard A Young8,14, Antonio Iavarone15, Anna Lasorella16, Jose M Silva5, John M Maris17,18,19, Andrea Califano20,21,22,23.
Abstract
High-risk neuroblastomas show a paucity of recurrent somatic mutations at diagnosis. As a result, the molecular basis for this aggressive phenotype remains elusive. Recent progress in regulatory network analysis helped us elucidate disease-driving mechanisms downstream of genomic alterations, including recurrent chromosomal alterations. Our analysis identified three molecular subtypes of high-risk neuroblastomas, consistent with chromosomal alterations, and identified subtype-specific master regulator proteins that were conserved across independent cohorts. A 10-protein transcriptional module-centered around a TEAD4-MYCN positive feedback loop-emerged as the regulatory driver of the high-risk subtype associated with MYCN amplification. Silencing of either gene collapsed MYCN-amplified (MYCNAmp) neuroblastoma transcriptional hallmarks and abrogated viability in vitro and in vivo Consistently, TEAD4 emerged as a robust prognostic marker of poor survival, with activity independent of the canonical Hippo pathway transcriptional coactivators YAP and TAZ. These results suggest novel therapeutic strategies for the large subset of MYCN-deregulated neuroblastomas.Significance: Despite progress in understanding of neuroblastoma genetics, little progress has been made toward personalized treatment. Here, we present a framework to determine the downstream effectors of the genetic alterations sustaining neuroblastoma subtypes, which can be easily extended to other tumor types. We show the critical effect of disrupting a 10-protein module centered around a YAP/TAZ-independent TEAD4-MYCN positive feedback loop in MYCNAmp neuroblastomas, nominating TEAD4 as a novel candidate for therapeutic intervention. Cancer Discov; 8(5); 582-99. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 517. ©2018 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29510988 PMCID: PMC5967627 DOI: 10.1158/2159-8290.CD-16-0861
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397